Speaker illustration

Professor Christopher Paul Cannon

Cardiovascular Division, Brigham and Women?s Hospital, Harvard Medical School, Boston (United States of America)

Christopher P. Cannon, MD Cardiovascular Innovation, Brigham and Women’s Hospital Professor of Medicine, Harvard Medical School, Boston, MA Remote faculty, Clinician-Scientist, CPC Clinical Research Institute Dr. Cannon is a Professor of Medicine at Harvard Medical School, and senior physician in the Cardiovascular Division at Brigham and Women’s Hospital. He serves as Education Director in the Cardiovascular Innovation group, and has recently joined the remote faculty as a Clinician Scientist at the CPC Clinical Research Institute. In the past, he has worked as an investigator in the TIMI Study Group. He has been principal investigator of more than 20 multicenter clinical trials, including TACTICS-TIMI 18, PROVE IT, IMPROVE IT, RE-DUAL PCI and VERTIS-CV trials. At Cardiovascular Innovation, he is helping implement quality improvement programs using telemedicine for lipids, hypertension and diabetes, and at CPC Clinical Research as he is helping lead pragmatic clinical trials.

Antithrombotic therapy in atrial fibrillation patients post-percutaneous coronary intervention: guidance from both sides of the Atlantic

Event: ESC CONGRESS 2019

Topic: Atrial Fibrillation (AF)

Session type: Satellite Symposium - Experts on the Spot

Thumbnail

NOACs in patients undergoing cardiac procedures

Event: ESC CONGRESS 2019

Topic: Atrial Fibrillation (AF)

Session type: Satellite Symposium

Thumbnail

Meet the trialist - ASCEND - Randomized trial of aspirin versus placebo for primary cardiovascular prevention in 15,480 people with diabetes & Randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 people with diabetes

Event: ESC Congress 2018

Topic: Diabetes and the Heart

Session type: Late-Breaking Science

Thumbnail

Translating trials to clinical practice: is dual therapy the new standard of care for atrial fibrillation patients post-PCI?

Event: ESC Congress 2018

Topic: Atrial Fibrillation (AF)

Session type: Satellite Symposium

Thumbnail

Bringing order to complexity: antithrombotic regimens for atrial fibrillation patients who underwent percutaneous coronary intervention

Event: ESC Congress 2018

Topic: Atrial Fibrillation (AF)

Session type: Satellite Symposium - Experts on the Spot

Thumbnail

ESC ATLAS of Cardiology: statistics on cardiovascular disease and care

Event: ESC Congress 2018

Topic: European Society of Cardiology

Session type: Special Session

Thumbnail

Antithrombotic strategies post-PCI in atrial fibrillation: new insights, new approach

Event: ESC CONGRESS 2017

Topic: Atrial fibrillation (AF)

Session type: Satellite Symposium - Experts on the Spot

Thumbnail

RE-DUAL PCI and reversal: improving care decisions after coronary revascularisation

Event: ESC CONGRESS 2017

Topic: Atrial fibrillation (AF)

Session type: Satellite Symposium

Thumbnail

Predicting and preventing acute events in patients with stable coronary artery disease

Event: ESC CONGRESS 2017

Topic: Angina pectoris stable

Session type: Advances in Science

Thumbnail

PSCK9 inhibition: a new horizon in LDL-C management

Event: ESC CONGRESS 2017

Topic: Lipids

Session type: Satellite Symposium - Experts on the Spot

Thumbnail

This platform is supported by

logo Novo Nordisk